Come see the latest addition to the proven UroLiftTM 2 System platform. Visit booth #1223 to experience this new UroLiftTM 2 System with Advanced Tissue Control up close and learn the benefits of going gold.
Get hands-on experience with the latest UroLift™ System technology in our simulator room
Meet with our experts for product demonstrations
Learn how the UroLift™ System:
- Is a proven earlier treatment alternative to BPH medications1
- Provides superior patient experience** among leading BPH procedures2-4
- Is the only BPH MIST with consistent durability in real world and clinical trials1,2
THE UROLIFTTM 2 SYSTEM WITH ADVANCED TISSUE CONTROL
Designed for all prostate types.*
Innovating on the #1 minimally invasive BPH treatment chosen by urologists and patients in the U.S.,5 the UroLiftTM 2 ATC System simplifies treatment for urologists and combines the proven platform benefits with improved tissue control – for greater confidence.6
ADVANCED PRACTICE PROVIDERS: LEARN WITH YOUR PEERS
We are proud to sponsor the first APP Educational Breakfast. This is a unique opportunity for APPs to learn about BPH care management and the transformational shift that is underway, catalyzed by the profound impact of APPs.
Sunday, May 5
Advancing BPH Care: Role of APPs in A New Era of Diagnosis and Treatment
Speakers: Erin Dwyer, MSN, FNP-C and Matt Ashley, MD**
6:45 A.M. to 7:30 A.M.
Hemisfair Ballroom 2
GAIN INSIGHTS FROM THE LATEST DATA
Learn about the latest clinical evidence being added to one of the most studied BPH MIST procedures. View these five abstracts about the UroLift™ System and hear from the lead investigators at AUA2024.
Saturday, May 4
Real-World Analysis of Hospitalizations and Emergency Department Visits Following Surgical Treatments for Benign Prostatic Hyperplasia (BPH) Reveal Distinctions Between Minimally Invasive and Traditional Surgery
Presenter: Steve Kaplan****
7:00 a.m.–9:00 a.m.
Sunday, May 5
The Early Patient Experience Following Treatment with PUL and WVTT, Two Contemporary MISTs for BPH: Preliminary Results from the CLEAR Study
Presenter: Claus Roehrborn***
7:00 a.m.–9:00 a.m.
Total Procedural Context is Crucial in Understanding BPH Treatment Device Safety in the FDA’s MAUDE Database
Presenter: Raj Shinghal***
7:00 a.m.–9:00 a.m.
Preliminary RCT Analysis of Minimally Invasive Surgery vs. Medication in the Initial Treatment of BPH-Associated LUTS
Presenter: Claus Roehrborn***
1:24 p.m.–1:32 p.m.
A US Healthcare Claims Analysis Reveals Post-surgery Medication Use Through 5 years Is Similar Between PUL, TURP and GreenLight
Presenter: Steve Kaplan****
3:30 p.m.–5:30 p.m.
Indicated for the treatment of symptoms of an enlarged prostate up to 100cc in men 45 years or older. As with any medical procedure, individual results may vary. Most common side effects are temporary and include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence.7 Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Consult the Instructions for Use (IFU) for more information.
CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician.
**Patient experience defined as a combination of rapid symptom relief, low risk profile, and preservation of sexual function
***Matt Ashley is an employee of Teleflex. Erin Dwyer, Claus Roehrborn, and Rajesh Shinghal are paid consultants of Teleflex.
**** Steven Kaplan is not a paid consultant of Teleflex.
1. Roehrborn, Can J Urol 2017 ; 2. Kaplan, Prostate Cancer Prostatic Dis 2023 ; 3. Gratzke, BJU Int 2016 ; 4. Tutrone, Can J Urol 2020; 5. U.S. 2022 estimates based on US Market Model 2022-24 (5-17-22 FINAL), which is in part based on Symphony Health PatientSource® 2018-21, as is and with no representations/warranties, including accuracy or completeness. ; 6. Data on file ; 7.Roehrborn, J Urology 2013
Teleflex, the Teleflex logo, UroLift, UroLift ATC, and the UroLift logo are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.